FDA Expands Pitolisant Label to Include Cataplexy Treatment in Pediatric Narcolepsy Patients
Key Insights
The FDA has approved pitolisant (WAKIX) for treating cataplexy (search) in pediatric patients aged 6 years and older with narcolepsy (search), making it the only non-scheduled therapy approved for both pediatric and adult narcolepsy patients.
This supplemental approval expands the existing pediatric indication, which previously covered only excessive daytime sleepiness (search), to now include cataplexy (search) treatment in children.
Harmony Biosciences is advancing next-generation formulations including pitolisant GR and HD, with patent applications extending market exclusivity to 2044 and projected revenues exceeding $1 billion by 2026.
The FDA has approved an expanded indication for pitolisant (WAKIX) to include treatment of cataplexy (search) in pediatric patients aged 6 years and older with narcolepsy (search), according to Harmony Biosciences. This supplemental approval makes pitolisant the only non-scheduled therapy approved in the United States for both pediatric and adult patients with narcolepsy with or without cataplexy.
"With this approval, clinicians now have the option to prescribe WAKIX to treat excessive daytime sleepiness (search), cataplexy (search), or both, in patients 6 years and older with narcolepsy (search)," noted Kumar Budur, MD, MS, Chief Medical and Scientific Officer of Harmony Biosciences.
Regulatory Timeline and Mechanism of Action
Pitolisant's regulatory journey began with its initial approval in August 2019 for excessive daytime sleepiness (search) in adult patients with narcolepsy (search). The indication was expanded in October 2020 to include cataplexy (search) in adults, and in June 2024, the agency approved pitolisant for excessive daytime sleepiness in pediatric patients aged 6 years and older. The current approval extends the pediatric indication to include cataplexy.
The drug is a selective histamine 3 receptor (search) antagonist and inverse agonist. Although the precise mechanism of action is not fully established, its efficacy is believed to be mediated through histamine 3 receptor activity, leading to increased synthesis and release of histamine, a wake-promoting neurotransmitter. Pitolisant received orphan drug designation for narcolepsy (search) in 2010 and breakthrough therapy designation for cataplexy (search) in 2018.
Safety Profile and Clinical Data
In placebo-controlled trials in patients with narcolepsy (search) with or without cataplexy (search), the most common adverse reactions in adults were insomnia, nausea, and anxiety. In pediatric trials, headache and insomnia were most frequently reported. The overall adverse reaction profile of pitolisant in the pediatric clinical trial was similar to that seen in the adult clinical trial program.
Pitolisant is contraindicated in patients with known hypersensitivity to the drug or with severe hepatic impairment. The medication prolongs the QT interval and should be avoided in patients with known QT prolongation, a history of cardiac arrhythmias, or other risk factors for torsade de pointes.
Next-Generation Formulations and Market Expansion
Harmony Biosciences is advancing multiple next-generation formulations to extend the pitolisant franchise. The company recently reported encouraging data from its pivotal bioequivalence study for pitolisant gastro-resistant (GR), demonstrating that the new 17.8 mg GR formulation is bioequivalent to the currently approved 17.8 mg WAKIX tablets, with comparable AUC and Cmax ratios.
The dosing optimization study showed that all participants were able to begin treatment at the full therapeutic dose of 17.8 mg without titration. "We are very pleased to have demonstrated bioequivalence for pitolisant GR which, along with the positive findings from our dosing optimization study, confirms its potential as a differentiated next-generation treatment option for narcolepsy (search) patients," said Budur.
Harmony plans to file a New Drug Application for pitolisant GR in early 2026, targeting a PDUFA decision in the first quarter of 2027. The company projects net revenue between $1.0 billion to $1.04 billion for WAKIX for the full year ending December 31, 2026.
Disease Background and Unmet Need
Narcolepsy (search) is a rare, chronic neurologic disorder characterized by sleep-wake instability that affects approximately 170,000 people in the United States. The condition is defined by excessive daytime sleepiness (search) and cataplexy (search), along with other manifestations of rapid eye movement sleep dysregulation, including hallucinations and sleep paralysis. In most patients, narcolepsy is associated with loss of hypocretin (search) or orexin (search) signaling in the brain.
Approximately 80-90% of patients with narcolepsy (search) experience gastrointestinal symptoms, and pitolisant GR is designed to minimize the worsening of these symptoms. The company has submitted utility patent applications covering both pitolisant GR and pitolisant HD formulations, which may extend market exclusivity to 2044.